Supplementary Methods S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Key Points

MAIN FINDING: Toripalimab shows promise as a second-line therapy for advanced hepatocellular carcinoma.
KEY EVIDENCE: Multicenter, open-label trial design supports the use of toripalimab in this patient group.
APPROACH: Study involved careful patient enrollment and clear statistical analysis methods to evaluate outcomes.
SIGNIFICANCE: Findings may help improve treatment options for patients with advanced hepatocellular carcinoma.

Phase I study assessed toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma, suggesting new treatment options.

Supplementary Methods S1. Supplementary details of study design, patient enrollment, statistical analysis and sample size calculation.

No takes yet. Share an insight, caveat, or question.

Zhang et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share